



## Subscription of shares supported by warrants of series TO3 begins today

Today, April 11, 2023, begins the exercise period for Alzinova AB's ("Alzinova" or the "Company") warrants of series TO3 (the "Warrants"), which were issued in connection with the Company's rights issue of units that was completed in June 2022. The exercise period lasts until April 25, 2023. Each Warrant entitles the holder to subscribe for one (1) new share in the Company at a price of SEK 2.17 per share. In order for the Warrants not to expire without value, it is required that the holder actively subscribes for shares no later than April 25, 2023, or alternatively sells the Warrants no later than April 21, 2023.

Complete terms and conditions and letter to warrant holders of series TO3 is available on the Company's campaign page at [www.to3.alzinova.com](http://www.to3.alzinova.com).

### Summarized terms for the Warrants:

**Exercise period:** April 11, 2023 – April 25, 2023.

**Subscription price:** SEK 2.17 per share.

**Issue volume:** 12,967,612 Warrants. If all the Warrants are exercised, 12,967,612 shares are issued, and the Company will receive approximately SEK 28.1 million before issuing costs.

**Last day for trading with Warrants:** April 21, 2023.

**Share capital and dilution:** If all Warrants are exercised the share capital will increase with SEK 3,410,481.956, from SEK 8,526,205.942 to SEK 11,936,687.898. The number of shares will increase with 12,967,612 shares if all Warrants are exercised, from 32,416,034 shares to 45,386,646 shares. The dilution at full exercise of all Warrants amounts to approximately 28.6 percent of the number of shares and votes in the Company.

Note that the Warrants that are not exercised at the latest April 25, 2023, or sold at the latest April 21, 2023, will expire without value. For the Warrants not to lose their value, the holder must actively subscribe for new shares or sell the Warrants. Please observe that some nominees may close their registration earlier than April 25, 2023.

### How the Warrants are exercised:

#### Nominee-registered warrants (custody account)

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.



### **Direct-registered warrants (securities account)**

No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.

Instructions for subscription are available at Alzinovas campaign page, [www.to3.alzinova.com](http://www.to3.alzinova.com) and on Mangold Fondkommission AB's website, [www.mangold.se](http://www.mangold.se).

### **Advisers**

Mangold Fondkommission AB is the financial adviser, Fredersen Advokatbyrå AB is the legal adviser and Shark Communication is the communication adviser to the Company in connection with the exercise of the Warrants.

### **For questions regarding the Warrants, please contact:**

Mangold Fondkommission AB  
E-mail: [emissioner@mangold.se](mailto:emissioner@mangold.se)

### **For more information, please contact:**

Kristina Torfgård, CEO  
Tel. +46 708 46 79 75  
E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

*Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.*

### **About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

### **Attachments**

**Subscription of shares supported by warrants of series TO3 begins today**